levofloxacina 500mg tabletas recubiertas
vesalius pharma, s.a.s - levofloxacina - levofloxacina....500.00 mg
levofloxacina sandoz 500 mg tabletas recubiertas
sandoz gmbh - levofloxacina (hemihidrato) - levofloxacina (hemihidrato)....500mg
moxifloxacina 400 mg tabletas recubiertas.
laboratorios la santÉ, s.a. - moxifloxacina (clorhidrato) - moxifloxacina (clorhidrato) ....400.00 mg
levofloxacina 500 mg comprimidos recubiertos
eurofarma guatemala, s.a. - levofloxacina (hemihidrato) - levofloxacina (hemihidrato)....500.00 mg
levofloxacina 750 mg mk tabletas recubiertas
tecnoquÍmicas, s.a - levofloxacina (hemihidrato) - levofloxacina (hemihidrato)....750.00 mg
levofloxacina qualipharm 500 mg/ 100 ml solución inyectable infusion i.v.
laboratorio qualipharm, s.a. - levofloxacina (hemihidrato) - levofloxacina (hemihidrato)....5.00 mg.
xepi ozenoxacin cream
medimetriks pharmaceuticals, inc. - ozenoxacin (unii: v0lh498rfo) (ozenoxacin - unii:v0lh498rfo) - ozenoxacin 10 mg in 1 g
axa-levo (levofloxacina 500 mg /100 ml) solucion inyectable infusion i.v.
axa parenterals, ltd - levofloxacina (hemihidrato) - levofloxacina (hemihidrato)....500,00 mg
levogyl (levofloxacina) 5 mg/ ml solucion para infusion i.v,
n/a - levofloxacina (hemihidrato) - levofloxacina (hemihidrato)....500,00 mg
xepi- ozenoxacin cream
biofrontera inc. - ozenoxacin (unii: v0lh498rfo) (ozenoxacin - unii:v0lh498rfo) - xepi™ is indicated for the topical treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes in adult and pediatric patients 2 months of age and older [see clinical studies (14)] . none. risk summary there are no available data on the use of xepi in pregnant women to inform a drug associated risk. systemic absorption of xepi in humans is negligible following topical administration of xepi (up to twice the concentration of the marketed formulation) [see clinical pharmacology (12.3)] . due to the negligible systemic exposure, it is not expected that maternal use of xepi will result in fetal exposure to the drug. animal reproduction studies were not conducted with xepi. however, toxicity studies conducted in pregnant rats and rabbits administered the oral form of ozenoxacin showed no significant adverse developmental effects (at >10,000 times the maximum human plasma concentration seen with dermal application of ozenoxacin). the estimated background risk of major birth defects and miscarriag